Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
INSP 
Inspire Medical Systems Inc (INSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/11/2025: INSP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit -16.09% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/11/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.70B USD | Price to earnings Ratio 90.27 | 1Y Target Price 232.93 |
Price to earnings Ratio 90.27 | 1Y Target Price 232.93 | ||
Volume (30-day avg) 541120 | Beta 1.48 | 52 Weeks Range 123.00 - 257.40 | Updated Date 04/1/2025 |
52 Weeks Range 123.00 - 257.40 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.67% | Operating Margin (TTM) 13.3% |
Management Effectiveness
Return on Assets (TTM) 3.04% | Return on Equity (TTM) 8.48% |
Valuation
Trailing PE 90.27 | Forward PE 72.99 | Enterprise Value 4273420032 | Price to Sales(TTM) 5.9 |
Enterprise Value 4273420032 | Price to Sales(TTM) 5.9 | ||
Enterprise Value to Revenue 5.31 | Enterprise Value to EBITDA 65.6 | Shares Outstanding 29759700 | Shares Floating 29198554 |
Shares Outstanding 29759700 | Shares Floating 29198554 | ||
Percent Insiders 1.1 | Percent Institutions 115.65 |
Analyst Ratings
Rating 4.25 | Target Price 239.6 | Buy 4 | Strong Buy 8 |
Buy 4 | Strong Buy 8 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Inspire Medical Systems Inc
Company Overview
History and Background
Inspire Medical Systems Inc. was founded in 2007. It focuses on developing and commercializing minimally invasive solutions for obstructive sleep apnea (OSA). The company's key milestone was the FDA approval of its Inspire therapy in 2014, which has driven its growth since.
Core Business Areas
- Inspire Therapy: This segment involves the development, manufacturing, and commercialization of the Inspire system, a neurostimulation technology for treating obstructive sleep apnea. It's their primary revenue driver.
- Physician Training and Support: This segment focuses on training physicians on the implantation and management of the Inspire system and providing ongoing support.
Leadership and Structure
The CEO is Tim Herbert. The company has a typical corporate structure with departments for research and development, sales and marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Inspire Therapy System: Inspire Therapy is a neurostimulation device implanted in the upper chest that delivers mild stimulation to key airway muscles during sleep, keeping the airway open. Competitors include CPAP machines from ResMed (RMD) and Philips (PHG). Inspire has the only FDA approved neurostimulation device for OSA, giving them a unique market position. Market share is constantly evolving as the business grows and can fluctuate but currenty hovers around 25-30% of the eligible market.
Market Dynamics
Industry Overview
The obstructive sleep apnea (OSA) market is large and underserved, with a significant portion of patients non-adherent to traditional therapies like CPAP. This creates a demand for alternative treatments.
Positioning
Inspire Medical Systems is positioned as a leader in alternative OSA treatments, specifically targeting patients who are CPAP-intolerant or seeking a more permanent solution. Its competitive advantage lies in its unique neurostimulation technology and clinical trial results.
Total Addressable Market (TAM)
The total addressable market (TAM) for OSA treatment is estimated to be several billion dollars. Inspire is focused on capturing a significant share of the CPAP-intolerant segment. Estimates range from $10 billion to $20 billion with the CPAP-intolerant.
Upturn SWOT Analysis
Strengths
- FDA-approved, unique technology
- Strong clinical evidence
- High patient satisfaction rates
- Dedicated sales force and training programs
Weaknesses
- Relatively high cost of the Inspire system
- Surgical procedure required
- Limited long-term data (compared to CPAP)
- Requires specialized surgical skills and training
Opportunities
- Expanding market awareness and patient education
- Increasing insurance coverage
- Developing next-generation Inspire technologies
- Geographic expansion
Threats
- Competition from established CPAP manufacturers
- Potential emergence of new OSA treatments
- Adverse events related to the Inspire system
- Changes in healthcare regulations or reimbursement policies
Competitors and Market Share
Key Competitors
- RMD
- PHG
Competitive Landscape
Inspire's advantage is its unique technology. However, it faces competition from companies with established distribution networks and a wider range of products.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Inspire has experienced strong historical growth, driven by increased adoption of its therapy and expansion into new markets.
Future Projections: Future growth is projected to continue, based on analyst estimates of continued adoption and market penetration. Numerical estimates require specific financial forecasts.
Recent Initiatives: Recent initiatives include expanding the sales force, increasing marketing efforts, and conducting clinical trials to support new indications.
Summary
Inspire Medical Systems is a growing medical device company with a unique and effective therapy for obstructive sleep apnea. Its revenue growth is driven by increased adoption of its technology. The company should be looking out for competitors and regulatory changes as it continues to increase market share. The relatively high cost and need for specialized surgical expertise could impact growth.
Similar Companies
- RMD
- PHG
- MEDP
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inspire Medical Systems Inc
Exchange NYSE | Headquaters Golden Valley, MN, United States | ||
IPO Launch date 2018-05-03 | Founder, Chairman, CEO & President Mr. Timothy P. Herbert | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1246 | Website https://www.inspiresleep.com |
Full time employees 1246 | Website https://www.inspiresleep.com | ||
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.